Nakayama, Takahiro

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Swain, S. M., Miles, D., Kim, S.-B., Im, Y.-H., Im, S.-A., Semiglazov, V., Ciruelos, E., Schneeweiss, A., Loi, S., Monturus, E., et al. (2020) · The Lancet Oncology

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 922

GSTP 1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER‐negative breast cancer

Miyake, T., Nakayama, T., Naoi, Y., Yamamoto, N., Otani, Y., Kim, S. J., Shimazu, K., Shimomura, A., Maruyama, N., Tamaki, Y., et al. (2012) · Cancer Science

Breast Cancer Treatment StudiesGlutathione Transferases and Polymorphisms

Cited by 146